These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39028654)

  • 21. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
    Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
    Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
    [No Abstract]   [Full Text] [Related]  

  • 22. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
    Bortz C; Armistead I; Bonaguidi A; Coyle DT
    J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioid treatment program culture and philosophy: Views of OTP staff and state officials on implementing interim methadone treatment.
    Burruss-Cousins K; Mitchell SG; Gryczynski J; Whitter M; Fuller D; Ibrahim A; Schwartz RP
    J Subst Use Addict Treat; 2024 Feb; 157():209265. PubMed ID: 38103832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic.
    Perry A; Wheeler-Martin K; Hasin DS; Terlizzi K; Mannes ZL; Jent V; Townsend TN; Pamplin JR; Crystal S; Martins SS; Cerdá M; Krawczyk N
    Drug Alcohol Depend; 2023 Dec; 253():111023. PubMed ID: 37984034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
    Nguyen T; Andraka-Christou B; Simon K; Bradford WD
    J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails.
    Flanagan Balawajder E; Ducharme L; Taylor BG; Lamuda PA; Kolak M; Friedmann PD; Pollack HA; Schneider JA
    JAMA Netw Open; 2024 Sep; 7(9):e2434704. PubMed ID: 39316401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
    Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care.
    Taylor JL; Laks J; Christine PJ; Kehoe J; Evans J; Kim TW; Farrell NM; White CS; Weinstein ZM; Walley AY
    Drug Alcohol Depend; 2022 Jul; 236():109497. PubMed ID: 35607834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
    Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
    Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 37. Care Integration for Hepatitis C Virus Treatment Through Facilitated Telemedicine Within Opioid Treatment Programs: Qualitative Study.
    Dickerson SS; George SJ; Ventuneac A; Dharia A; Talal AH
    J Med Internet Res; 2024 Jun; 26():e53049. PubMed ID: 38865703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
    Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
    Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions.
    Thomas CP; Stewart MT; Ledingham E; Adams RS; Panas L; Reif S
    JAMA Netw Open; 2023 Mar; 6(3):e232052. PubMed ID: 36884250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
    Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
    J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.